The 14-gene testing has shown advantage in the case the molecular high-risk EGFR-mutant NSCLC patients too and has contributed in accurately identifying the target population, and the resultant reallocation of population previously receiving inadequate EGFR-TKI into molecular-high-risk have subsequently shown survival benefit.[23] The FLAURA trial showed similar results on the utility of EGFR mutation profiling using cobas for patient selection and treatment with Osimertinib, on such EGFR TKI.[24]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.